Kidney disease affects a large number of adults, yet many people still do not realise they have it. Vereci Dx is using the end of National Kidney Month to stress that awareness should not fade when the campaign calendar ends. Its argument is straightforward: education and early detection remain important throughout the year because delayed diagnosis can leave patients at greater risk and reduce the opportunity for timely intervention.
Vereci Dx is drawing attention to the fact that kidney disease is both common and often undetected. That combination makes awareness a practical issue rather than a symbolic one. If more people understand the risks and recognise the value of testing earlier, the chances of identifying disease before it progresses may improve.
A condition that affects many people but remains under-recognised presents a clear case for better education and stronger detection pathways.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
